Last update: Aug. 22, 2019
Not risky for breastfeeding or infant.
Aminoglycoside antibacterial active on Gram positive, Gram negative and Mycobacterium tuberculosis bacteria.
Given its nephrological and otological toxicity, its most frequent current use is topically (dermal or intestinal) although it is still used in some countries intravenously.
It is excreted in breastmilk in moderate quantities (Lactmed 2018: Amiraslanova 1985, Matsuda 1984, Vorherr 1974), and even large quantities (Briggs 2017, Tran 1998, O'Brien 1974). An infant exposed during pregnancy and breastfeeding to kanamycin and other anti-tuberculosis drugs did not present clinical problems due to the medication (Drobac 2005).
Kanamycin, like all other aminoglycosides, has very low oral bioavailability (Briggs 2017, Chin 2001), which impedes transfer from breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
It is important to take into account possible false negative cultures in febrile infants whose mothers take antibiotics, as well as the possibility of gastroenteritis due to altered intestinal flora (Briggs 2017, Arbex 2010, Ito 1993).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM